Our approach to drug development and commercialization
Recent achievements and milestones
We completed the dosing of the first patient cohort in the phase 1 clinical trial with our novel anti-cancer drug MSP008-22. To learn more about this first-in-human patient trial visit www.clinicaltrials.gov.
We completed the dosing of the first two cohorts of healthy volunteers in the
phase 1 clinical trial with our novel anti-cancer drug MSP008-22. To learn more about this first-in-human healthy individual trial visit www.clinicaltrials.gov.
The healthy volunteer trial titled “A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers” was initiated in April 2023.
Our first-in-human patient trial titled “A Single Ascending Dose, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetic Profile of MSP008-22 in Patients with Advanced Solid Tumors” was initiated in January 2023.
Patent for MSP008-22 anti-cancer compound granted in USA and Japan.
Patent for Synthesis of Cleistanthin A and its derivatives thereof granted in India, USA, Germany, Netherlands, France, UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.
Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa
We believe that cancer is a complicated disease with a solution that requires comprehensive expertise from various disciplines that can work together harmoniously. That is exactly what we have built over the years to bring our product to patients successfully.
We are dedicated to pushing the boundaries of oncology research. Our medicinal chemistry and drug design teams have developed a pipeline of novel anti-cancer molecules with diverse modes-of-action. The cancer biology team works with various CROs in order to validate the anti-tumor properties of these drugs during preclinical development. Our lead candidate, MSP008-22, has shown promising results in preclinical models against various cancer types including Triple Negative Breast Cancer and Prostate Cancer.
Additionally, it has also shown efficacy against COVID-19 during preclinical development indicating its potential as an anti-viral molecule.. We have also initiated the first-in-human Phase I trial in patients with advanced solid tumors and in healthy volunteers to test for safety, toxicity, pharmacokinetics.
Sathgen’s Intellectual Property portfolio includes a global coverage for all its pipeline molecules. We plan to commercialize our products through partnerships with other pharmaceutical and biotech companies around the world.